Original language | English (US) |
---|---|
Pages (from-to) | 1062-1064 |
Number of pages | 3 |
Journal | Annals of neurology |
Volume | 88 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2020 |
Funding
J.R.C.: funded by a Sylvia Lawry Physician Fellowship grant, the National Multiple Sclerosis Society; E.G.: nothing to report; B.P.M.: research funding for investigator‐initiated studies, Roche; site Principal Investigator for studies sponsored by Roche; speaking fees, Genzyme; consulting fees, Roche; owns stock, Pfizer; S.D.N.: scientific advisory boards, Biogen, Genentech, Celgene, Novartis, Greenwich Biosciences, EMD Serono; clinical trial clinical adjudication committee member, BioIncept, Autobahn Therapeutics, medDay Pharmaceuticals; grant/research funding (paid directly to institution), Biogen, Genentech, National Multiple Sclerosis Society, Department of Defense, and Patient Centered Outcomes Institute.
ASJC Scopus subject areas
- Clinical Neurology
- Neurology